title: Amphiphile-induced heart muscle-cell (myocyte) injury: effects of intracellular fatty acid overload.
abstract: Lipid amphiphile toxicity may be an important contributor to myocardial injury, especially during ischemia/reperfusion. In order to investigate directly the potential biochemical and metabolic effects of amphiphile overload on the functioning heart muscle cell (myocyte), a novel model of nonesterified fatty acid (NEFA)-induced myocyte damage has been defined. The model uses intact, beating neonatal rat myocytes in primary monolayer culture as a study object and 5-(tetradecyloxy)-2-furoic acid (TOFA) as a nonmetabolizable fatty acid. Myocytes incubated with TOFA accumulated it as NEFA, and the consequent NEFA amphiphile overload elicited a variety of cellular defects (including decreased beating rate, depletion of high-energy stores and glycogen pools, and breakdown of myocyte membrane phospholipid) and culminated in cell death. The amphiphile-induced cellular pathology could be reversed by removing TOFA from the culture medium, which resulted in intracellular TOFA "wash-out." Although the development and severity of amphiphile-induced myocyte injury could be correlated with both the intracellular TOFA/NEFA content (i.e., the level of TOFA to which the cells were exposed) and the duration of this exposure, removal of amphiphile overload did not inevitably lead to myocyte recovery. TOFA had adverse effects on myocyte mitochondrial function in situ (decoupling of oxidative phosphorylation, impairing respiratory control) and on myocyte oxidative catabolism (transiently increasing fatty acid beta oxidation, citric acid cycle flux, and glucose oxidation). The amphiphile-induced bioenergetic abnormalities appeared to constitute a state of "metabolic anoxia" underlying the progression of myocyte injury to cell death. This anoxic state could be ameliorated to some extent, but not prevented, by carbohydrate catabolism.
authors.affiliation: Department of Pharmacology and Chemotherapy, Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey 07110.
authors.forename: D R
authors.initials: DR
authors.lastname: Janero
authors.forename: C
authors.initials: C
authors.lastname: Burghardt
authors.forename: D
authors.initials: D
authors.lastname: Feldman
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D055598:Chemical Phenomena; D002621:Chemistry; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D005663:Furans / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000378:metabolism; D007700:Kinetics; D008563:Membrane Lipids / Q000378:metabolism; D008854:Microscopy, Electron; D008929:Mitochondria, Heart / Q000378:metabolism; D008954:Models, Biological; D009206:Myocardium / Q000166:cytology / Q000378:metabolism* / Q000648:ultrastructure; D010084:Oxidation-Reduction; D010085:Oxidative Phosphorylation; D010743:Phospholipids / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D005230:Fatty Acids, Nonesterified; D005663:Furans; D000960:Hypolipidemic Agents; D008563:Membrane Lipids; D010743:Phospholipids; C014289:5-(tetradecyloxy)-2-furancarboxylic acid; D000255:Adenosine Triphosphate; D006003:Glycogen; D005947:Glucose